<DOC>
	<DOCNO>NCT00663442</DOCNO>
	<brief_summary>Children 6-17 evaluate ADHD blood sample obtain DNA extraction . If eligible , participate 4 week , double blind , placebo control trial weekly switch . In randomized order , child receive 18 , 36 , 54 mg. OROS methylphenidate placebo . Each week , parent report measure , clinical interview , safety assessment conduct . Hypothesis : Efficacy adverse event dose dependent . Dopamine Transporter Genotype predict response</brief_summary>
	<brief_title>Basic Clinical Research Attention Deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>617 DSM IV criterion ADHD Parents willing complete measure Mental retardation psychoses seizure disorder</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>ADHD</keyword>
	<keyword>side effect</keyword>
	<keyword>sleep</keyword>
	<keyword>dopamine</keyword>
	<keyword>pharmacogenetics</keyword>
</DOC>